verified SJR 1,202 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Taylor and Francis Ltd.

workspace_premium Q1 — Pharmacology lock Subscription

Cancer Biology and Therapy

Cancer Biology and Therapy is a journal indexed in SJR in Pharmacology and Molecular Medicine with an H index of 134. It has an SJR impact factor of 1,202 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,202.

Cancer Biology and Therapy focuses its scope in these topics and keywords: cancer, cells, tumor, proliferation, progression, expression, cell, therapy, gene, vitro, ...

ISSN: 1538-4047

Publisher: Taylor and Francis Ltd.

Category: Pharmacology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,202 Q1

H-index 134

Acceptance rate pie_chart

23% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,202

H-index

134

Docs (year)

112

Docs 3y

208

Total refs

5983

Cites 3y

885

Citable 3y

206

Cites/Doc 2y

4.71

Ref/Doc

53.42

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway

What accounts for the variable responses to progesterone on Schwann cells from mice and humans - the species-specific influence or the paracrine effects from the tumor microenvironment?

Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner

CXCR4/TGF-beta1 mediated self-differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and promoted colorectal carcinoma development

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells

Clinical significance of B7-H1(PD-L1)expression in human acute leukemia

Circulating tumor cells count and characterization in a male breast cancer patient

Chromatin Remodeling and Cancer

Capsaicin reactivates hMOF in gastric cancer cells and induces cell growth inhibition

Breast cancer stem-like cells show dominant homologous recombination due to a larger S-G2fraction

Breast cancer bone metastases: Combination therapy targeting cancer cells and the tumor microenvironment

SHOW MORE ARTICLES

Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2

15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer

Antitumor effects of a natural anthracycline analog (Aloin) involve altered activity of antioxidant enzymes in HeLaS3 cells

Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells

AMPK signaling: A targetable tumor suppressor pathway?

Allosteric AKT inhibitors as a targeted cancer therapy

Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice

A translational end-run for a rare, genetically enigmatic tumor

A preclinical188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49

A Novel Methionine-Based Signaling Mechanism Regulating the Expression of Thymidylate Synthase

A new look at molecular biology of breast cancer

A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement

FAQs

Cancer Biology and Therapy has an SJR of 1,202 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Cancer Biology and Therapy is 23%.

Cancer Biology and Therapy

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Cancer Biology and Therapy?

What is the APC / publication cost?

What is the acceptance rate?